Analysts Anticipate BioLineRx Ltd. (NASDAQ:BLRX) to Post -$0.13 Earnings Per Share

Wall Street analysts predict that BioLineRx Ltd. (NASDAQ:BLRX) will announce ($0.13) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for BioLineRx’s earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.10). BioLineRx reported earnings of ($0.30) per share during the same quarter last year, which indicates a positive year over year growth rate of 56.7%. The firm is scheduled to report its next earnings report on Monday, November 22nd.

On average, analysts expect that BioLineRx will report full-year earnings of ($0.73) per share for the current financial year. For the next financial year, analysts forecast that the firm will report earnings of ($0.56) per share, with EPS estimates ranging from ($0.65) to ($0.47). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow BioLineRx.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Wednesday, August 18th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03).

Separately, Zacks Investment Research lowered shares of BioLineRx from a “hold” rating to a “sell” rating in a report on Monday, May 31st.

Shares of BioLineRx stock traded down $0.09 on Monday, reaching $2.81. The stock had a trading volume of 333,147 shares, compared to its average volume of 2,771,460. The stock has a market capitalization of $132.84 million, a P/E ratio of -2.11 and a beta of 2.11. BioLineRx has a 1 year low of $1.40 and a 1 year high of $6.34. The company has a quick ratio of 6.76, a current ratio of 6.76 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $2.93 and a 200 day moving average price of $2.96.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. First Heartland Consultants Inc. acquired a new stake in BioLineRx in the first quarter valued at $28,000. Silverarc Capital Management LLC acquired a new position in shares of BioLineRx during the 1st quarter worth $558,000. Intellectus Partners LLC acquired a new position in shares of BioLineRx during the 1st quarter worth $113,000. Millennium Management LLC acquired a new position in shares of BioLineRx during the 2nd quarter worth $42,000. Finally, Virtu Financial LLC acquired a new position in shares of BioLineRx during the 2nd quarter worth $47,000. 2.98% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its oncology programs include Motaxafortide (BL-8040), which is therapy platform used in the treatment of pancreatic cancer; and AGI-134 is a immunotherapy treatment used fro multiple solid tumors. The company was founded in April 2003 and is headquartered in Modi’in, Israel.

Further Reading: How is a Moving Average Calculated?

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.